open access

Vol 21, No 4 (2014)
Original articles
Submitted: 2013-06-22
Accepted: 2013-09-07
Published online: 2014-08-29
Get Citation

Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up

Piotr Lodziński, Marek Kiliszek, Edward Koźluk, Agnieszka Piątkowska, Paweł Balsam, Janusz Kochanowski, Piotr Scisło, Radosław Piątkowski, Grzegorz Opolski
DOI: 10.5603/CJ.a2013.0144
·
Cardiol J 2014;21(4):384-391.

open access

Vol 21, No 4 (2014)
Original articles
Submitted: 2013-06-22
Accepted: 2013-09-07
Published online: 2014-08-29

Abstract

Background: The aims of the study are 1) to assess antiarrhythmic prophylaxis efficacy dur­ing the first 2 months after radiofrequency ablation (ARF) due to AF; 2) to define risk factors for early AF recurrence (EAFR) after ARF; 3) to determine the long-term follow-up results and risk factors for late AF recurrence (LAFR).

Methods: A total number of 210 consecutive patients who had undergone ARF due to AF were analyzed. Patients were randomized into three groups: Group 1 (G1), without any anti­arrhythmic drug (AAD); Group 2 (G2), with amiodarone or sotalol; Group 3 (G3), with last ineffective AAD. The study was designed to analyze two periods: short-term observation, the first 2 months after ARF; and at least 2 years of long-term follow-up.

Results: After 2 months, clinical data were collected from 171 patients (123 males, mean age of 50.3 years; persistent AF in 19.8%; lone AF in 36.6%). Sinus rhythm (SR) was maintained in 84 (49.1%) patients; 35 (20.4%) patients presented with a single episode of AF, 39 (23%) patients experienced a reduction in number of AF episodes, and 13 (7.5%) patients showed no improvement. No predisposing factor for early recurrence was found. After a mean follow-up of 55 months, clinical data were collected in 137 patients, of which 47 (34%) maintained SR. Those more likely to sustain SR were: males (82.9% vs. 62.2%; p = 0.018), younger patients (44.8 ± 12.7 vs. 52.5 ± 9.9; p = 0.0001), patients with smaller left atrium diameter (4.05 ± ± 0.49 cm vs. 4.25 ± 0.51 cm; p = 0.04), and those without any AF recurrence during the first 2 months after ARF (78.7% vs. 35.6%; p < 0.0001). In the multivariable analysis, the inde­pendent risk factors for LAFR were hypertension (p < 0.001) and persistent AF (p = 0.014).

Conclusions: Antiarrhythmic prophylaxis does not affect the number of AF recurrences during the first 2 months after ablation. SR maintenance during a blanking period after AF ablation is a positive prognostic factor in long-term follow-up. Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation.

Abstract

Background: The aims of the study are 1) to assess antiarrhythmic prophylaxis efficacy dur­ing the first 2 months after radiofrequency ablation (ARF) due to AF; 2) to define risk factors for early AF recurrence (EAFR) after ARF; 3) to determine the long-term follow-up results and risk factors for late AF recurrence (LAFR).

Methods: A total number of 210 consecutive patients who had undergone ARF due to AF were analyzed. Patients were randomized into three groups: Group 1 (G1), without any anti­arrhythmic drug (AAD); Group 2 (G2), with amiodarone or sotalol; Group 3 (G3), with last ineffective AAD. The study was designed to analyze two periods: short-term observation, the first 2 months after ARF; and at least 2 years of long-term follow-up.

Results: After 2 months, clinical data were collected from 171 patients (123 males, mean age of 50.3 years; persistent AF in 19.8%; lone AF in 36.6%). Sinus rhythm (SR) was maintained in 84 (49.1%) patients; 35 (20.4%) patients presented with a single episode of AF, 39 (23%) patients experienced a reduction in number of AF episodes, and 13 (7.5%) patients showed no improvement. No predisposing factor for early recurrence was found. After a mean follow-up of 55 months, clinical data were collected in 137 patients, of which 47 (34%) maintained SR. Those more likely to sustain SR were: males (82.9% vs. 62.2%; p = 0.018), younger patients (44.8 ± 12.7 vs. 52.5 ± 9.9; p = 0.0001), patients with smaller left atrium diameter (4.05 ± ± 0.49 cm vs. 4.25 ± 0.51 cm; p = 0.04), and those without any AF recurrence during the first 2 months after ARF (78.7% vs. 35.6%; p < 0.0001). In the multivariable analysis, the inde­pendent risk factors for LAFR were hypertension (p < 0.001) and persistent AF (p = 0.014).

Conclusions: Antiarrhythmic prophylaxis does not affect the number of AF recurrences during the first 2 months after ablation. SR maintenance during a blanking period after AF ablation is a positive prognostic factor in long-term follow-up. Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation.

Get Citation

Keywords

pulmonary vein isolation, atrial fibrillation, early AF recurrence, late AF recurrence

About this article
Title

Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up

Journal

Cardiology Journal

Issue

Vol 21, No 4 (2014)

Pages

384-391

Published online

2014-08-29

Page views

2059

Article views/downloads

1927

DOI

10.5603/CJ.a2013.0144

Bibliographic record

Cardiol J 2014;21(4):384-391.

Keywords

pulmonary vein isolation
atrial fibrillation
early AF recurrence
late AF recurrence

Authors

Piotr Lodziński
Marek Kiliszek
Edward Koźluk
Agnieszka Piątkowska
Paweł Balsam
Janusz Kochanowski
Piotr Scisło
Radosław Piątkowski
Grzegorz Opolski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl